Abstract:
Myeloproliferative neoplasms are a diverse group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform to a secondary acute myeloid leukemia that is ultimately fatal. Triapine is a novel ribonucleotide reductase inhibitor of the M2 subunit. Sequential inhibition of ribonucleotide reductase with triapine and an M1 ribonucleotide reductase inhibitor (fludarabine) was noted to be safe, and led to a 29% complete plus partial response rate in myeloproliferative neoplasms. This manuscript reports a phase 2 trial of triapine (105 mg/m 2 /day) followed by fludarabine (30 mg/m 2 /day) daily for 5 consecutive days in 37 patients with accelerated myeloproliferative neoplasms and secondary acute myeloid leukemia. The overall response rate was noted to be 49% (18/37), with a complete remission rate of 24% (9/37). Overall response rates and complete remissions were seen in all disease subsets, including secondary acute myeloid leukemia, where the overall response rate and complete remission rate was 48% and 33%, respectively. All patients with known JAK2 V617F mutations (6/6) responded. The median overall survival of the entire cohort was 6.9 months, with a median overall survival of both overall responders and complete remissions of 10.6 months. These data further demonstrate the promise of simultaneous inhibition of ribonucleotide reductase in patients with accelerated myeloproliferative neoplasms and secondary acute myeloid leukemia. This study was registered with clinical trials.gov (NCT00381550).
Introduction:
Myeloproliferative neoplasms (MPNs) are a diverse group of disorders that include polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML), and primary myelofibrosis (MF), while chronic myelomonocytic leukemia (CMML) and atypical (Philadelphia-negative) CML are classified as overlap syndromes of MPN and myelodysplastic syndrome (MDS). There are approximately 23,000 new cases of MPNs (including CMML) per year in the United States; these diseases lead to significant amounts of morbidity and mortality.
1,2 While MPNs may have protracted chronic phases, they often accelerate and many eventually transform to an ultimately fatal acute leukemia. Patients with MPNs in accelerated phase, CML in blast crisis (CML-BC), and secondary acute myeloid leukemia (AML) in transformation have a dismal prognosis. In a large retrospective analysis, patients with secondary AML transformed from MF were shown to have a median overall survival (OS) of < 3 months. 3 Allogeneic stem cell transplantation (alloSCT) benefits select patients; however, alloSCT is limited by the older age of MPNs at presentation, increased rates of transplant-related mortality, and unknown optimal timing. [4] [5] [6] Thus, development of novel safe and effective strategies in aggressive MPNs continues to represent a pressing need.
Ribonucleotide reductase is an enzyme that converts ribonucleotides into deoxyribonucleotides and is therefore a pivotal enzyme in the processes of DNA synthesis, DNA damage repair, and cellular growth and survival. Inhibition of ribonucleotide reductase depletes the intracellular pools of deoxyribonucleotides and their triphosphorylated forms (dNTPs). Ribonucleotide reductase is composed of two subunits: a regulatory (M1) subunit, which is inhibited by nucleoside analogs, and a catalytic (M2) subunit, which requires iron and generation of a tyrosyl free radical for activity. 7 Hydroxyurea effectively inhibits the M2 subunit, and has been clinically used for decades in patients with AML, CML, CMML and other MPNs. [8] [9] [10] [11] [12] Triapine, a novel thiosemicarbazone derivative, is an extremely potent inhibitor of the M2 subunit of ribonucleotide reductase (100-1000 fold more potent than HU), and has been studied as a single agent in hematologic malignancies with demonstrable safety and clinical activity.
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Multiple studies have shown that inhibition of either the M1 (via fludarabine, Given the promising results of schedule A, we designed and conducted a phase 2 study of triapine 105 mg/m 2 daily followed by fludarabine 30 mg/m 2 daily for 5 days in 37 patients with aggressive MPNs and secondary AML transformations. We confirm our previous findings that this combination of agents is clinically active in accelerated MPNs and secondary AMLs derived from MPNs, and further identify the JAK2 V617F mutation as a potential predictor of response to ribonucleotide reductasesequential inhibition.
Methods:
Patient Eligibility: Patients were eligible to receive additional cycles of treatment until disease progression or toxicity.
Measurement of Toxicities:
Non-hematologic toxicities were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Treatment of triapine was interrupted for grade 3 non-hematologic toxicities for up to 48
hours. All subsequent doses were held until toxicity resolved to grade < 1 (or baseline).
Measurement of Response:
BM aspiration and biopsies were performed prior to treatment, during week 3 of the first cycle, at the time of hematologic recovery from all cycles of therapy (defined as neutrophil count > 500/mm 3 and platelets > 20,000/mm 3 independent of transfusion), or at any time that leukemia regrowth was suspected. .
Statistical Considerations:
The primary objectives of this study were to determine the efficacy and toxicity of triapine followed by fludarabine in patients with aggressive MPNs. The study was designed to detect an improvement in overall response rate from 10-30% with a twosided type 1 error rate of 5% and 90% power using a two-stage approach. A stopping requirement was placed such that the study would terminate if < 3 out of 18 patients had a response. An additional 24 patients were planned but the study was completed after 37 total patients were enrolled due to drug availability.
OS was calculated from the first day of treatment to death or last known follow-up and estimated using the Kaplan-Meier method. A landmark analysis 37 was used to compare response groups using day 42 of treatment as the landmark time. OS was compared between patient groups using Cox proportional hazard models, adjusting for age and gender. The database was locked on June 1, 2013. Analyses were completed using statistical freeware R version 3.0.1.
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Results:
Patient Characteristics:
The pretreatment clinical demographics of the 37 patients enrolled on this trial are outlined in analysis was performed on 20/37 (54%) patients, with 6/20 (30%) patients having a detectable JAK2 V617F mutation.
Toxicity:
A total of 100 cycles of triapine and fludarabine were administered to 37 patients, with a median of 3 cycles per patient (range: 1-6). Nine out of 37 (24%) patients received > 4 cycles of therapy. Early death (prior to day 30) occurred in 4/37 (11%) patients (secondary AML: n=2, CML: n=2) due to sepsis (n=2), multi-organ failure (n=1), and cardiogenic shock (n=1).
As depicted in Table 2 , there were 6 > grade 4 toxicities: 2 grade 4 acidosis, 1 grade 4 acute kidney injury, 1 grade 5 acute respiratory distress syndrome , and 2 grade 5 sepsis. There were 66 total grade > 3 toxicities seen with 100 total cycles given, of which 33 (50%) were transiently related to triapine infusion. These toxicities manifested as pneumonitis (19%: defined as hypoxia and/or dyspnea directly related to triapine infusion), acidosis (9%), methemoglobinemia > 15% (3%), and anaphylaxis (2%), and were reversed rapidly with supportive care without recurrence. There were 3
cases of clinical methemoglobinemia > 15% (range: 15-16.2%) while on this study, 2 patients required methylene blue for severe symptoms. The most common non-triapine infusional toxicities were hepatic (12%) and infectious (10%) toxicities. Ten (27%)
patients required dose reductions of triapine, predominantly due to infusional related toxicities of triapine. No patient required more than 1 dose reduction with triapine. An additional 9 (24%) patients required dose reductions of fludarabine because of transient decreases in creatinine clearance to < 60 ml/min.
Clinical Outcomes:
The overall response rate of triapine and fludarabine in this patient population was 49% (18/37). In the first stage, 9 of 18 patients achieved a response, with 9 of the remaining 19 patients achieving a response in the second stage. Overall, 9 patients achieved a CR (24%) (including 1 patient with CR with incomplete platelet recovery), 4
patients achieved a PR (11%), and 5 patients achieved HI (14%). An additional 5 patients had stable disease for at least 1 cycle. As outlined in Table 3 , the overall response rate for each disease subset was: CMML 57% (4/7), MPN 60% (3/5), CML-BC 25% (1/4), and secondary AML 48% (10/21). Of the 9 patients achieving a CR, 7 had secondary AML (antecedent MPN: n=5, antecedent CMML: n=2), 1 had CML-BC (achieved a complete cytogenetic response) and 1 had CMML. The secondary AML patients derived from MPN that achieved a CR (n=5/13) were further sub-classified based on recent response criteria, defined by Mascarenhas et al. 36 Four out of the 5 CR 1 1 response-complete) with continued fibrosis seen on subsequent bone marrow biopsies, while 1/5 CR patients had a CR with complete molecular response, and no evidence of a chronic MPN state by morphology. The overall response rates were further broken down into specific clinical risk factors (Table 4 ). The median age of responders was 65 years. Of note, the two oldest patients on study were 75 years (both with secondary AML) and both achieved CR on study. Fifty percent of patients with splenomegaly had an overall response to therapy, with 8/10 responding patients also having improvement in both symptoms and size of splenomegaly (as measured by physical exam and/or radiologic findings). Additionally, 41% (7/17) of patients with poor-risk cytogenetics (all of which had either complex and/or monosomal karyotype) responded, with 2/7 patients having complete cytogenetic clearance, and 1/7 patients with partial cytogenetic clearance of a complex karyotype. Only 1/7 patients who received prior azacitidine therapy had a response (CMML: HI).
All 6 patients with a JAK2 V617F mutation had a response, including 3/6 (50%) achieving a CR. In comparison, the overall response rate in patients with wild type JAK2 was 29% (4/14 patients, p = 0.01), with an overall CR rate of 14% (2/14 patients, p = 0.13). Each of the 3 patients with JAK2 V617F mutations achieving a CR had secondary AML arising from MPN (MF: n=2, ET: n=1). The 2 patients who achieved a CR with a known wild type JAK2 had secondary AML (from antecedent CMML: n=1) and CML-BC (n=1).
The median OS of the study population was 6.9 months (95% CI: 4.3-10.7 months), with 6 month and 12 month OS rates 54% and 24%, respectively. The median OS of responders (CR, PR, HI) and CR patients was 10.6 months (95% CI: 8.7-15. Three patients (CML: n=2, CMML: n=1) died of alloSCT complications (infection: n = 2, hepatic sinusoidal obstructive syndrome: n = 1), including the 2 patients who achieved a CR, and 2 patients relapsed post-alloSCT. One patient with secondary AML (arising from CMML) achieved stable disease on study and then had a nonmyeloablative haploidentical alloSCT (5 months after enrolling on study), with subsequent relapse 17 months after alloSCT, and is alive in CR for > 15 months after re-induction cytotoxic therapy and donor lymphocyte infusion.
Discussion:
MPNs continue to present a major therapeutic challenge, especially once they undergo aggressive transformation. This phase II study involving triapine, a novel ribonucleotide reductase M2 inhibitor, combined with fludarabine (M1ribonucleotide reductase inhibitor), extends our initial observations that this regimen has clinical activity in aggressive/accelerated phase MPNs including transformations to AML. This study met its primary end point of having an overall response rate > 30% (49%). The CR rate of 24% is promising in this heavily pretreated patient population. Patients with secondary AML had an overall response rate and CR rate of 48% and 33%, respectively, which is particularly promising in this patient population with a dismal prognosis. There did not seem to be an upper age limit of responders, as patients responded to therapy up through the age of 75 years. Landmark analyses comparing responders to non-responders by day 42 of treatment did not reveal significant differences in OS. This landmark analysis, however, has its limitations. Forty-two days was chosen prior to study accrual as the time in which an initial response rate should be noted for each patient on study. However, 7/9 CR patients achieved a CR after day 42 of treatment (range: 21-96 days), and these 7 patients were thus listed as non-CR for statistical comparisons using the landmark analysis. Additionally, if a patient who had a PR or HI before day 42 went on to achieve a CR after day 42, this response was not specifically included in the specific comparison of CR versus no CR for the landmark statistical comparisons.
Nonetheless, the clinical responses were short lived, with a median duration of response of 4 months, emphasizing the high degree of chemo-resistance seen in accelerated MPNs. Moreover, the median OS of 6.9 months underscores the extremely poor prognosis of the patient population in this study. Because of the short duration of response, this combination of agents may work best as a bridge to further therapy, such as an alloSCT. However, only 5 patients were able to receive an alloSCT after treatment with these agents (including 4/5 deaths), which may reflect the older age of patients on study (median age: 64 years). Three of the 5 patients who were able to receive an alloSCT received myeloablative preparative regimens. As alloSCT techniques become more refined, it may be possible to select patients who may benefit from a nonmyeloablative preparative regimen versus a myeloablative regimen.
The combination of triapine and fludarabine led to unique toxicities, most notably acute pulmonary toxicities, such as methemoglobinemia and metabolic acidosis. These toxicities are distinctively related to the triapine infusion. Although these toxicities were not inconsequential, they often resolved promptly without intervention and without subsequent organ dysfunction. Upon dose reduction of triapine in ten patients, there
were no additional grade > 3 toxicities.
Simultaneous inhibition of the M1 and M2 subunit of ribonucleotide reductase is a concept worthy of further exploration in patients with accelerated MPNs. Although triapine has 100-1000 fold more potency than hydroxyurea, triapine has never been compared with hydroxyurea for therapeutic efficacy. It would be rational to further explore hydroxyurea in combination with other cytotoxic agents and M1 ribonucleotide reductase inhibitors (such as fludarabine, gemcitabine and clofarabine) for synergistic ribonucleotide reductase inhibition. This approach may be better tolerated than the combination of triapine and fludarabine. Given the epigenetic dysregulation seen in patients with accelerated MPNs (with or without transformation to AML), additional treatment approaches for these patients include hypomethylating agents, such as azacitidine. 40 Thepot et al. evaluated the use of azacitidine in 54 patients with AML or MDS secondary to MPNs, with an overall response rate and CR rate of 52% and 24%, respectively, with a median OS of 11 months. 41 However, in AML patients, the CR rate (including CR with incomplete count recovery) was only 11%. As in our study, the duration of response was short (9 months); nonetheless azacitidine still represents another promising treatment strategy for patients in this high-risk group, either as a bridge to an alloSCT or for symptomatic improvement. Unfortunately, the response was poor in the subset of patients in this study who received prior azacitidine therapy (1/7 overall response rate). The majority of these patients (6/7) had secondary AML, and it is possible that prior azacitidine use changes the biology of the disease to a more aggressive, treatment-resistant disease, though the small numbers of patients on this study preclude any significant generalizations or conclusions.
Since this study was conceived and executed, novel JAK2 inhibitors, such as ruxolitinib, have emerged as integral parts of the therapeutic armamentarium for MPNs. 42 Given the encouraging results of this study, simultaneous inhibition of the M1 and M2 subunits of ribonucleotide reductase should be investigated with JAK2
inhibitors, either in combination or in sequence. Hydroxyurea was shown in one study to increase STAT-5 phosphorylation in a dose-dependent manner, thus leading to activation of the STAT-JAK pathway. 43 Combining lower doses of hydroxyurea with a JAK2 inhibitor would theoretically overcome this potentially deleterious activation. There are other reports, however, that suggest that hydroxyurea has a preferential effect in patients with JAK2 V617F mutations with high allele burden. 44 Given the high response rates seen on study in patients with JAK2 V617F mutations, it would be noteworthy to explore whether M2 ribonucleotide reductase inhibitors or whether combination ribonucleotide reductase inhibition has any significant impact on JAK2 allele burden. 
